Recruiting
Phase 1

LY3867070

Sponsor:

Eli Lilly and Company

Code:

NCT07021547

Conditions

Healthy

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

LY3867070

Placebo

Study Details

Brief summary:

The purpose of this study is to evaluate how well LY3867070 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Conditions

Healthy

Study ID

NCT07021547

Start date

May 27, 2025

Status verified date

Jun, 2026

Completion date

Aug, 2026

Anticipated

Primary completion date

Aug, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Are overtly healthy as determined by medical evaluation
  • Part C of the study includes only Japanese and Chinese participants
  • Have a body weight greater than or equal to 45 kilogram (kg) and also body mass index 18 to 32 kilogram per square meter (kg/m²) inclusive

Exclusion Criteria:

  • Have a history or presence of multiple or severe allergies, anaphylactic reaction to prescription or nonprescription drugs, or history of significant atopy
  • Have a significant history or current thyroid disease
  • Have a significant history of or current psychiatric disorders, rheumatologic, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (such as Cushing syndrome and hyperaldosteronism), hematological, or neurological disorders
  • Are smokers (including electronic cigarettes) within 6 months prior to screening and unwilling to refrain from smoking for the duration of the study.
  • Unwilling to undergo skin biopsies (for Part B only)
  • Are unwilling to have body hair cut or shaved in cases where hair, in the investigator's opinion, could interfere with noninvasive skin patch

Study Design

Enrollment

196 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: LY3867070 (Part A)

Single-Ascending Dose of LY3867070 administered orally

experimental: LY3867070 (Part B)

Multiple-Ascending Doses of LY3867070 administered orally

experimental: LY3867070 (Part C)

Multiple Doses of LY3867070 administered orally

placebo comparator: Placebo (Parts A-C)

Placebo administered orally

experimental: LY3867070 (Part D)

Drug-Drug Interaction (DDI) administered orally

Interventions

LY3867070

Administered orally

Placebo

Administered orally

Primary outcome measure

  • Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline up to Approximately Week 7 ]
  • Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline up to Approximately Week 7 ]
  • Number of Participants with One or More Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline up to Approximately Week 7 ]

Central Contacts and Locations

Central contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

1-317-615-4559LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

Locations

Anaheim Clinical Trials, LLC

Recruiting

Anaheim, California, United States, 92801

Contacts

714-774-7777, ext. 1012

Principal Investigator:

Amina Haggag

Fortrea Clinical Research Unit

Recruiting

Dallas, Texas, United States, 75247

Contacts

866-429-3700

Principal Investigator:

Gene Voskuhl

More Information

Sponsor

Eli Lilly and Company

Last update posted

Jun 3, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Eli Lilly and Company on 2026-06-03.